R31.9

Hematuria, unspecified

## Overview of Hematuria, Unspecified (R31.9)Hematuria, specified by ICD-10 code R31.9, refers to the presence of red blood cells (RBCs) in the urine when the specific type or cause is not identified. It is a common clinical finding that warrants thorough investigation as it can indicate a wide range of underlying conditions, from benign to life-threatening. Hematuria is broadly classified into microscopic hematuria (blood detectable only under a microscope) and gross hematuria (visible blood in the urine, making it appear pink, red, or cola-colored). The unspecified nature of R31.9 means that initial investigations are ongoing, or a definitive cause has not yet been established.### PathophysiologyThe presence of RBCs in the urine signifies a breach in the integrity of the urinary tract, from the renal glomeruli to the urethral meatus. The pathophysiology depends on the origin of the bleeding. Generally, hematuria can be categorized as glomerular or non-glomerular.#### Glomerular HematuriaThis type results from damage to the glomerular basement membrane, allowing RBCs to pass into Bowman's capsule and subsequently into the urine. Characteristic features include dysmorphic (abnormally shaped) RBCs and red blood cell casts on urine microscopy. Conditions leading to glomerular hematuria include various forms of glomerulonephritis (e.g., IgA nephropathy, post-infectious glomerulonephritis, lupus nephritis), Alport syndrome, and thin basement membrane disease. The primary mechanism involves inflammation or structural defects within the glomeruli.#### Non-Glomerular HematuriaNon-glomerular hematuria can originate from any part of the urinary tract distal to the glomeruli. The RBCs in this type are typically isomorphic (normal shape) and red blood cell casts are absent.Potential sources include:1. **Renal (non-glomerular)**: Kidney stones (nephrolithiasis), pyelonephritis (kidney infection), renal cell carcinoma, polycystic kidney disease, renal trauma, renal tuberculosis, and papillary necrosis. These conditions cause bleeding by mechanical disruption, inflammation, or tumor invasion.2. **Ureteral**: Ureteral stones, ureteral tumors.3. **Bladder**: Cystitis (bladder infection), bladder cancer, bladder stones, radiation cystitis, interstitial cystitis.4. **Prostatic**: Benign prostatic hyperplasia (BPH), prostatitis, prostate cancer.5. **Urethral**: Urethritis, urethral strictures, urethral trauma.6. **Other**: Exercise-induced hematuria, anticoagulant use, sickle cell trait/disease, arteriovenous malformations.### Clinical PresentationThe presentation of hematuria can vary significantly.#### Gross HematuriaPatients typically present with visible reddish or brownish urine. It can be continuous or intermittent, and the color may fluctuate. Accompanying symptoms often provide clues to the etiology: dysuria (painful urination), frequency, urgency, and suprapubic pain suggest cystitis; flank pain radiating to the groin with nausea/vomiting points to nephrolithiasis; painless gross hematuria, especially in older patients or smokers, raises concern for malignancy (bladder or renal cancer). The presence of blood clots can indicate substantial bleeding.#### Microscopic HematuriaThis is often asymptomatic and discovered incidentally during a routine urinalysis. Despite being occult, microscopic hematuria requires evaluation, especially in populations at risk for serious underlying conditions. Symptoms, if present, are related to the underlying cause rather than the hematuria itself.### Diagnostic CriteriaThe diagnosis of hematuria is confirmed by urinalysis demonstrating the presence of three or more red blood cells per high-power field (HPF) on two out of three properly collected urine specimens, in the absence of obvious benign causes (e.g., menstruation, vigorous exercise).For gross hematuria, a single episode is sufficient for diagnosis.Dipstick tests are useful screening tools, sensitive to hemoglobin, but can yield false positives (e.g., myoglobinuria, presence of oxidizing agents) and false negatives (e.g., high vitamin C intake). Therefore, microscopic examination of urine sediment is essential for confirmation and characterization of RBCs.### Standard of CareThe primary goal in managing unspecified hematuria is to identify and treat the underlying cause. The evaluation typically follows an algorithmic approach based on the type of hematuria (gross vs. microscopic) and patient risk factors (age, smoking history, exposure to toxins, family history of urologic disease).#### Initial Evaluation1. **History and Physical Examination**: Detailed history focusing on urinary symptoms, pain, medication use (especially anticoagulants), recent trauma, infections, exercise, and family history. Physical exam includes blood pressure, abdominal palpation, and in men, a digital rectal exam.2. **Urinalysis with Microscopy**: Confirms hematuria, assesses RBC morphology (dysmorphic suggests glomerular origin, isomorphic suggests non-glomerular), and checks for casts, proteinuria, pyuria, and bacteriuria.3. **Blood Tests**: Renal function (serum creatinine, BUN), electrolytes, complete blood count (CBC), and sometimes coagulation studies.#### Further InvestigationsBased on initial findings and risk stratification:1. **Imaging Studies**: Renal ultrasound is often the first-line imaging. CT urogram (CT with contrast of kidneys, ureters, bladder) is highly sensitive for stones, tumors, and structural abnormalities. MRI may be used in specific situations (e.g., contrast allergy, pregnancy).2. **Cystoscopy**: Direct visualization of the bladder and urethra is often recommended, particularly for gross hematuria or in patients with risk factors for bladder cancer, to detect tumors, stones, or inflammatory lesions.3. **Urine Cytology**: Screening for malignant cells, though its sensitivity for low-grade bladder cancer is limited.4. **Nephrology Consultation**: Indicated for suspected glomerular disease (e.g., significant proteinuria, dysmorphic RBCs, RBC casts, impaired renal function), sometimes requiring a renal biopsy.#### TreatmentTreatment is highly specific to the identified cause: antibiotics for infections, lithotripsy or surgery for stones, surgical excision for tumors, or specific medical management for glomerular diseases (e.g., immunosuppressants). For asymptomatic microscopic hematuria with a negative workup, periodic monitoring is often recommended. When hematuria remains unspecified after a comprehensive workup, watchful waiting with periodic re-evaluation may be appropriate, considering the patient's risk profile and the persistence of hematuria.

Clinical Symptoms

  • Pink, red, or cola-colored urine (gross hematuria)
  • Microscopic blood in urine (asymptomatic)
  • Dysuria (painful urination)
  • Urinary frequency
  • Urinary urgency
  • Suprapubic pain
  • Flank pain
  • Abdominal pain
  • Groin pain
  • Nausea
  • Vomiting
  • Fever
  • Chills
  • Weight loss (unexplained)
  • Fatigue
  • Blood clots in urine

Common Causes

  • Kidney stones (nephrolithiasis)
  • Urinary tract infections (UTI), including cystitis, pyelonephritis, urethritis
  • Glomerulonephritis (e.g., IgA nephropathy, post-infectious glomerulonephritis, lupus nephritis)
  • Bladder cancer
  • Renal cell carcinoma
  • Prostate cancer
  • Benign prostatic hyperplasia (BPH)
  • Prostatitis
  • Polycystic kidney disease
  • Renal trauma
  • Bladder trauma
  • Urethral stricture
  • Sickle cell trait or disease
  • Anticoagulant therapy (e.g., warfarin, direct oral anticoagulants)
  • Vigorous exercise
  • Arteriovenous malformations in the urinary tract
  • Radiation cystitis
  • Interstitial cystitis
  • Papillary necrosis
  • Alport syndrome
  • Thin basement membrane disease
  • Urinary tract tuberculosis
  • Drug-induced nephropathy (e.g., NSAIDs, cyclophosphamide)

Documentation & Coding Tips

Always specify whether hematuria is gross (visible) or microscopic (detected only by lab tests). Gross hematuria often indicates a more serious underlying condition.

Example: Patient presents with new onset, painless, GROSS HEMATURIA, noted as dark red urine for the past 24 hours. No dysuria, frequency, or urgency. Initial urinalysis pending. Assessment: Gross hematuria, etiology unknown. Plan: URGENT referral to Urology for cystoscopy and imaging to rule out malignancy given the high-risk presentation. Billing Focus: Distinction between gross (R31.0) and microscopic (R31.1) is crucial for severity and investigative pathways. Risk Adjustment: Documenting 'gross hematuria' as a presenting symptom of a potential malignancy (e.g., bladder cancer) contributes to higher risk adjustment scores if the malignancy is subsequently confirmed, reflecting increased disease burden and resource utilization.

Billing Focus: Specifying 'gross' (R31.0) versus 'microscopic' (R31.1) hematuria guides appropriate coding for severity and subsequent diagnostic workup.

Document the associated symptoms, timing (e.g., initial, terminal, total hematuria), and presence of clots. These details are critical for localizing the source of bleeding.

Example: Patient reports intermittent MICROSCOPIC HEMATURIA, confirmed on repeat UA, associated with right flank pain radiating to the groin, and occasional dysuria. No visible clots. History of nephrolithiasis. Assessment: Microscopic hematuria likely secondary to recurrent right renal calculus (N20.0). Plan: Renal ultrasound today, urine culture, pain management, and follow-up with Urology. Billing Focus: Linking hematuria to specific symptoms (flank pain, dysuria) and a known cause (nephrolithiasis) allows for more specific coding (e.g., N20.0 for calculus with hematuria). Risk Adjustment: Documenting 'recurrent nephrolithiasis' as a chronic condition contributes to risk adjustment, particularly if associated with complications or requiring ongoing management, reflecting increased complexity and resource needs.

Billing Focus: Details like 'intermittent,' 'flank pain,' and 'clots' help differentiate etiologies and support higher specificity codes (e.g., N20.0 for calculus of kidney with hematuria).

Identify and document any known underlying causes or contributing factors for hematuria (e.g., UTI, renal calculus, anticoagulant use, prostate issues, recent trauma, malignancy).

Example: Patient on Warfarin for atrial fibrillation presents with new onset MICROSCOPIC HEMATURIA. INR is therapeutic at 2.5. No other symptoms reported. Assessment: Microscopic hematuria, likely anticoagulant-induced (D68.32). Plan: Continue Warfarin, monitor INR, repeat UA in 1 week, consider renal ultrasound if persistent. Advised patient on signs of worsening bleeding. Billing Focus: Documenting 'anticoagulant-induced hematuria' (D68.32, adverse effect of drug) is more specific than unspecified hematuria and links directly to medication management. Risk Adjustment: Documenting both the 'atrial fibrillation' (I48.91) and the 'anticoagulant-induced hematuria' (D68.32) accurately reflects the patient's comorbidities and medication-related complications, thereby enhancing the risk adjustment profile.

Billing Focus: Attributing hematuria to a specific cause (e.g., N39.0 for UTI, N20.0 for calculus, D68.32 for anticoagulant-induced) allows for more precise and higher-level coding.

Distinguish between transient/benign hematuria and persistent/pathological hematuria. Document follow-up plans for persistent cases.

Example: Follow-up visit for patient with previously documented transient microscopic hematuria after strenuous exercise. Repeat urinalysis today shows no hematuria. Assessment: Resolved transient microscopic hematuria (R31.1, Z09 for follow-up). Plan: Reassurance. No further workup needed at this time. Billing Focus: Documenting resolution and the transient nature prevents unnecessary extensive workup coding. Using R31.1 for microscopic and Z09 for follow-up ensures accurate billing for the visit. Risk Adjustment: Accurately documenting resolution prevents persistent elevation of risk scores for a condition that is no longer active, ensuring appropriate future resource allocation.

Billing Focus: Differentiating between transient and persistent hematuria (e.g., documenting 'resolved' or 'intermittent') informs the necessity of further diagnostic services and appropriate E/M leveling.

When hematuria is a manifestation of another condition (e.g., glomerulonephritis, polycystic kidney disease), code the underlying condition first, followed by the hematuria code (R31.x).

Example: Patient with known Type 2 Diabetes Mellitus (E11.22) and established Chronic Kidney Disease Stage 3 (N18.3) presents with new onset MICROSCOPIC HEMATURIA. Renal biopsy 3 months ago showed diabetic nephropathy. Assessment: Microscopic hematuria secondary to diabetic nephropathy (E11.22, N18.3, R31.1). Plan: Continue current diabetic and CKD management, monitor UA, consider nephrology consult for re-evaluation. Billing Focus: Coding the underlying conditions (E11.22, N18.3) as primary diagnoses followed by R31.1 for hematuria accurately reflects the patient's complete disease burden. Risk Adjustment: This sequencing is crucial. Documenting and coding the severe manifestations of diabetes (diabetic nephropathy, E11.22) and the specific stage of CKD (N18.3), both HCC conditions, along with the hematuria, significantly impacts the patient's risk adjustment factor, reflecting multiple severe chronic conditions requiring complex management.

Billing Focus: Proper sequencing, with the underlying condition (e.g., N03.x for chronic nephritic syndrome, N18.x for CKD) listed first, ensures appropriate reimbursement for the primary disease driving the manifestation.

Document negative findings from diagnostic workup to support the 'unspecified' nature if a definitive cause cannot be found after thorough investigation.

Example: Patient presented 3 months ago with microscopic hematuria. Extensive workup completed, including renal ultrasound, CT urogram, cystoscopy, and urine cytology, all negative for malignancy, calculi, or other structural abnormalities. Repeat UA today still shows microscopic hematuria. Assessment: Persistent microscopic hematuria of unknown etiology. Plan: Continue monitoring annually with UA, reassure patient regarding negative workup. Billing Focus: Documenting the extensive negative workup justifies the 'unspecified' code if no cause is found, supporting the medical necessity of the prior diagnostic services. Risk Adjustment: While 'unspecified' codes typically have lower impact, documenting comprehensive rule-out strategies demonstrates thorough care coordination and complexity, indirectly supporting higher E/M levels for visits where extensive workup is reviewed.

Billing Focus: If R31.9 is used after a comprehensive workup is negative, explicitly state 'etiology undetermined despite comprehensive workup' to justify its use.

Relevant CPT Codes

Related Diagnoses

Hierarchy